Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Moodys
Baxter
Mallinckrodt
Deloitte
Boehringer Ingelheim
Merck
McKinsey

Generated: September 22, 2018

DrugPatentWatch Database Preview

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE Drug Profile

« Back to Dashboard

Which patents cover Albuterol Sulfate And Ipratropium Bromide, and when can generic versions of Albuterol Sulfate And Ipratropium Bromide launch?

Albuterol Sulfate And Ipratropium Bromide is a drug marketed by Apotex Inc, Cipla Ltd, Fosun Pharma, Nephron, Ritedose Corp, Sun Pharma Global, Teva Pharms, and Watson Labs Teva. and is included in eight NDAs.

The generic ingredient in ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.

Summary for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Drug patent expirations by year for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Pharmacology for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

US Patents and Regulatory Information for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 077117-001 Dec 31, 2007 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 076724-001 Dec 31, 2007 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Nephron ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 076749-001 Dec 31, 2007 AN RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Watson Labs Teva ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 077063-001 Dec 31, 2007 AN RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Cipla Ltd ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 077559-001 Dec 31, 2007 AN RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fosun Pharma ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 076867-001 Dec 21, 2006 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Moodys
Baxter
Mallinckrodt
Deloitte
Boehringer Ingelheim
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.